Unknown

Dataset Information

0

A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001.


ABSTRACT: AIMS:To determine the efficacy of methylguanine methyltransferase (MGMT) depletion + BCNU [1,3-bis(2-chloroethyl)-1- nitrosourea: carmustine] therapy and the impact of methylation status in adults with glioblastoma multiforme (GBM) and gliosarcoma. METHODS:Methylation analysis was performed on GBM patients with adequate tissue samples. Patients with newly diagnosed GBM or gliosarcoma were eligible for this Phase III open-label clinical trial. At registration, patients were randomized to Arm 1, which consisted of therapy with O(6)-benzylguanine (O(6)-BG) + BCNU 40 mg/m(2) (reduced dose) + radiation therapy (RT) (O6BG + BCNU arm), or Arm 2, which consisted of therapy with BCNU 200 mg/m(2) + RT (BCNU arm). RESULTS:A total of 183 patients with newly diagnosed GBM or gliosarcoma from 42 U.S. institutions were enrolled in this study. Of these, 90 eligible patients received O(6)-BG + BCNU + RT and 89 received BCNU + RT. The trial was halted at the first interim analysis in accordance with the guidelines for stopping the study due to futility (<40 % improvement among patients on the O6BG + BCNU arm). Following adjustment for stratification factors, there was no significant difference in overall survival (OS) or progression-free survival (PFS) between the two groups (one sided p = 0.94 and p = 0.88, respectively). Median OS was 11 [95 % confidence interval (CI) 8-13] months for patients in the O6BG + BCNU arm and 10 (95 % CI 8-12) months for those in the BCNU arm. PFS was 4 months for patients in each arm. Adverse events were reported in both arms, with significantly more grade 4 and 5 events in the experimental arm. CONCLUSIONS:The addition of O(6)-BG to the standard regimen of radiation and BCNU for the treatment patients with newly diagnosed GBM and gliosarcoma did not provide added benefit and in fact caused additional toxicity.

SUBMITTER: Blumenthal DT 

PROVIDER: S-EPMC4465052 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4790106 | BioStudies
2019-01-01 | S-EPMC6847934 | BioStudies
2019-01-01 | S-EPMC6884550 | BioStudies
2018-01-01 | S-EPMC5963626 | BioStudies
2019-01-01 | S-EPMC6928109 | BioStudies
1000-01-01 | S-EPMC5788663 | BioStudies
2019-01-01 | S-EPMC6468745 | BioStudies
2019-01-01 | S-EPMC6591191 | BioStudies
2017-01-01 | S-EPMC5304294 | BioStudies
2020-01-01 | S-EPMC7641818 | BioStudies